Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Net Income: 2019-2025

Historic Net Income for Legend Biotech (LEGN) over the last 7 years, with Sep 2025 value amounting to -$38.5 million.

  • Legend Biotech's Net Income rose 66.98% to -$38.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$243.1 million, marking a year-over-year increase of 28.30%. This contributed to the annual value of -$177.0 million for FY2024, which is 65.84% up from last year.
  • According to the latest figures from Q3 2025, Legend Biotech's Net Income is -$38.5 million, which was up 69.04% from -$124.2 million recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Net Income peaked at $335.7 million during Q4 2022, and registered a low of -$557.1 million during Q3 2022.
  • Its 3-year average for Net Income is -$86.8 million, with a median of -$97.3 million in 2025.
  • Within the past 5 years, the most significant YoY rise in Legend Biotech's Net Income was 496.19% (2022), while the steepest drop was 32,288.91% (2022).
  • Quarterly analysis of 5 years shows Legend Biotech's Net Income stood at -$84.7 million in 2021, then surged by 496.19% to $335.7 million in 2022, then plummeted by 143.21% to -$145.0 million in 2023, then spiked by 111.68% to $16.9 million in 2024, then surged by 66.98% to -$38.5 million in 2025.
  • Its Net Income stands at -$38.5 million for Q3 2025, versus -$124.2 million for Q2 2025 and -$97.3 million for Q1 2025.